title: Acute encephalopathy with combination dabrafenib/trametinib therapy.
abstract: Biomarkers have improved the clinical application of numerous targeted agents used to treat solid tumors. In melanoma, the finding that approximately 60% of tumor cells harbor specific Val600 mutations of BRAF has increased the likelihood of response to certain agents aimed at inhibiting the mutant kinase. While dabrafenib is an effective anti-tumor agent with acceptable tolerability in patients with BRAF-mutated melanoma, we report the development (and outcome) of a previously unpublished acute toxic reaction observed in a patient receiving the drug.
authors.affiliation: 1 School of Pharmacy, Department of Clinical Pharmacy West Virginia University, Morgantown, WV, USA.
authors.forename: Jalyn
authors.initials: J
authors.lastname: Cooper
authors.affiliation: 2 School of Medicine, Section of Hematology/Oncology, Department of Clinical Pharmacy West Virginia University, Morgantown, WV, USA.
authors.forename: Dheeraj
authors.initials: D
authors.lastname: Kodali
authors.affiliation: 1 School of Pharmacy, Department of Clinical Pharmacy West Virginia University, Morgantown, WV, USA.|2 School of Medicine, Section of Hematology/Oncology, Department of Clinical Pharmacy West Virginia University, Morgantown, WV, USA.
authors.forename: Gerald M
authors.initials: GM
authors.lastname: Higa
mesh_terms: D000208:Acute Disease; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001927:Brain Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics; D010091:Oximes / Q000008:administration & dosage; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D011728:Pyridones / Q000008:administration & dosage; D011744:Pyrimidinones / Q000008:administration & dosage
chemical_list: D007093:Imidazoles; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib
keywords: Acute encephalopathy; BRAF V600 mutation; dabrafenib; melanoma